Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases

Video

In this video we discuss the use of concurrent immunotherapy and stereotactic radiosurgery for treatment of melanoma brain metastases.

A new retrospective study found that patients with melanoma brain metastases who were treated with immunotherapy and stereotactic radiosurgery (SRS) within a month of each other had more robust and rapid tumor shrinkage.

In this video, senior study author Veronica L. S. Chiang, MD, of the Department of Neurosurgery at the Yale School of Medicine in New Haven, Connecticut, discusses the results of the study. Click here to read more.

Recent Videos
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.
David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Related Content
Second Primary Cancer Risk is Similar in Adjuvant Cemiplimab Vs Placebo in Skin Cancer Subtype

Second Primary Cancer Risk is Similar in Adjuvant Cemiplimab Vs Placebo in Skin Cancer Subtype

Jax DiEugenio
October 18th 2025
Article

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

Caroline Seymour
October 18th 2025
Article

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

The primary end points of the trial included the incidence of dose-limiting toxicities with monotherapy and combination therapy and the incidence of treatment-emergent adverse events.

FDA Grants FTD to WTX-124 in Advanced Pretreated Cutaneous Melanoma

Tim Cortese
October 9th 2025
Article

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.

FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma

Tim Cortese
October 8th 2025
Article

Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.